Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Brain Neoplasms
  • Dacarbazine
  • Glioma

abstract

  • Twice-daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity. This regimen compares favorably with other dosing schedules of temozolomide reported in the literature.

publication date

  • March 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.23167

PubMed ID

  • 18246536

Additional Document Info

start page

  • 1139

end page

  • 46

volume

  • 112

number

  • 5